Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor

Journal of Clinical Pharmacology

Volumn 53, Issue 11, 2013, Pages 1168-1176

  Naderer, Odin J ^a   Jones, Lori S ^a   Zhu, John ^a   Kurtinecz, Milena ^a   Dumont, Etienne ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Dose escalation; Intravenous; Mesylate salt; Peptide deformylase inhibitor; Pharmacokinetics

Indexed keywords

GSK 1322322; PEPTIDE DEFORMYLASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INJECTION SITE IRRITATION; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER GASTROINTESTINAL BLEEDING;

DOSE ESCALATION; INTRAVENOUS; MESYLATE SALT; PEPTIDE DEFORMYLASE INHIBITOR; PHARMACOKINETICS;

ADMINISTRATION, ORAL; ADULT; AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXAMIC ACIDS; INFUSIONS, INTRAVENOUS; MALE;

EID: 84891505001     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.150     Document Type: Article

References (13)

1. Schmieder R, Edwards R. Insights into antibiotic resistance through metagenomic approaches. Future Microbiol. 2012;7:73-89.
2. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74:417-433.
3. Coates ARM, Halls G, Hu Y. Novel classes of antibiotics or more of the same Br J Pharmacol. 2011;163:184-194.
4. Lewandowski T, Peters T, Simon N, Kulkarni S. Potent activity of GSK1322322 a novel peptide deformylase inhibitor in a Haemophilus influenzae and Streptococcus pneumoniae respiratory tract infection model. Poster presented at: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA. Poster F12115.
5. Apfel CM, Locher H, Evers S, et al. Peptide deformylase as an antibacterial drug target: Target validation and resistance development. Antimicrob Agents Chemother. 2001;45:1058-1064.
6. Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011;1241:122-152.
7. Lewandowski T, DeMarsh P, Peters T, Kulkarni S. Potent activity of GSK1322322 a novel peptide deformylase inhibitor after oral dosing in a murine multidrug resistant Staphylococcus aureus infection. Poster presented at: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA. Poster F12113.
8. O'Dwyer K, Hackel M, Hightower S, et al. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob Agents Chemother. 2013;57:2333-2342.
9. Ross JE, ScangarellaOman NE, Miller LA, Sader HS, Jones RN. Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. J Clin Microbiol. 2011;49:3928-3930.
10. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. Singledose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother. 2013;57:2005-2009.
11. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: A randomized placebocontrolled study. J Antimicrob Chemother. 2013;68: 1901-1909.
12. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. Effect of H2 blockade and food on singledose pharmacokinetics of GSK1322322, a peptide deformylase inhibitor antibacterial. Antimicrob Agents Chemother. 2013;57:2556-2561.
13. Naderer OJ, Rodvold KA, Jones LS, Zhu JZ, Dumont EF. Penetration of GSK1322322 (GSK322) into epithelial lining fluid (ELF) and alveolar macrophages (AM) as determined by bronchoalveolar lavage (BAL). Poster presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA. Poster A1277.